Early Bayesian Dose Adjustment of Vancomycin Continuous Infusion in Children in a Randomized Controlled Trial
Romain Berthaud(Hôpital Necker-Enfants Malades), Sihem Benaboud(Université Paris Cité), Déborah Hirt(Université Paris Cité), Mathieu Genuini(Hôpital Necker-Enfants Malades), Mehdi Oualha(Hôpital Necker-Enfants Malades), Martin Castelle(Hôpital Necker-Enfants Malades), Coralie Briand(Hôpital Necker-Enfants Malades), S. Artru(Hôpital Necker-Enfants Malades), Lorenzo Norsa(Hôpital Necker-Enfants Malades), Olivia Boyer(Hôpital Necker-Enfants Malades), Frantz Foissac(Université Paris Cité), Naïm Bouazza(Université Paris Cité), Jean‐Marc Tréluyer(Hôpital Necker-Enfants Malades)
Cited by 24Open Access
Abstract
≤800mg-h/L.Ninety-nine patients were enrolled: 49 were randomized to the Bayesian group and 50 to the control group. Modified intention-to-treat analysis included 82 patients: 85% of Bayesian group patients achieved H24 vancomycin target versus 57% of control group patients (p=0.007) with no difference regarding iatrogenic events. Early Bayesian dose adjustment increased the proportion of children achieving vancomycin target at H24, which may improve clinical outcomes of methicillin-resistant staphylococcal infections.
Related Papers
No related papers found
Powered by citation graph analysis